Ann: FDA grants broader orphan drug status to PTX100 for TCLs, page-43

Subsequent to the PTX100 webinar, SYC also referenced an update on the PTX100 efficacy data in the Investor Briefing. At 11:30 he states, "We are about to put out another update... some short term news. I won't say any more on that." and at 12:24 he says, "Stayed tuned on that [case] study" .... referring to the patient who has left the trial deemed a complete response!

https://prescienttherapeutics.investorportal.com.au/

So, yeah, I think we are right in expecting an update this week. Dare say that the data is being collated and an announcement on its way any day now.